Patient-derived xenograft and organoid models reveal the potent efficacy of roblitinib (a selective inhibitor of FGFR4; also named as FGF-401) in both intrinsic and acquired anti-HER2 resistant breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.